iMAb delivers readily developable human antibodies for your pipeline

SERVICES

Antibody discovery includes:

In vitro selection and screening (on cells, proteins or peptides)
Human/mouse cross-reacting mAb
IgG reformatting (#species, #isotype, Fc KO or ADCC-enhanced)
Functional validation (agonist/antagonist/competition/inhibition/ADCC/CDC/...)

TECHNOLOGY

In vitro display technologies offer unique advantages over hybridoma technology, particularly for challenging targets like integral membrane proteins.

iMAb uses proprietary computer-designed synthetic repertoires of human mAbs optimized for diversity, expression, and affinity for in vitro screening.

ABOUT US

iMAb is a biotech company with an integrated approach to develop human antibodies.

The company was spun out from Inserm and uses proprietary know-how and a highly diverse library containing billions of candidate antibodies.

Highlights

Recognized team of experts in antibody discovery
Proprietary in vitro optimized human libraries
100% delivery track record as of today*

(*) > 30 (academic) programs including: GPCR agonists, enzyme inhibitors, anti-splicing-variants, anti-post-translational modifications, anti-receptor tyrosine kinases, anti-ligand, ... (many of them cross-reactive human/mouse)

Latest news

iMAb - Eutilex collaboration

July, 2020

iMAb and Eutilex partner to discover immune-oncology antibodies

iMAb - Domain Tx collaboration

June, 2020

iMAb and Domain Tx partner to discover antibody targeting an undisclosed GPCR target for IO therapy

Bio-Europe Spring - Paris, FRANCE

March 23-27, 2020

Meet iMAb at the 14th annual international partnering Bio-Europe conference

10th World ADC EUROPE - London, UK

March 2-5, 2020

Meet iMAb at the 10th annual World ADC-Europe

iMAb - SATT collaboration

January, 2020

iMAb and SATT NORD partner to discover therapeutic antibodies against cancer

11th annual PEGS EUROPE - Lisbon, Portugal

November 18-22, 2019

Meet iMAb at the 11th annual PEGS-Europe, Protein and Antibody Engineering Summit | Booth 438

New Fab library presentated at PEGS 2019 Lisbon by Pierre Martineau,

co-founder of iMAb

BIO-EUROPE 2019 - Hamburg, Germany

November 11-13, 2019

Meet iMAb at the 25th annual BIO-Europe, Europe's largest partnering conference serving the global biotechnology industry

FESTIVAL OF BIOLOGICS 2019 - basel switzerland

October 15-17, 2019

Meet iMAb at the Festival of Biologics, Europe’s most important gathering of senior health and biologic professionals

iMAb - Servier collaboration

September, 2019

iMAb and Servier join forces to discover therapeutic antibodies against autoimmune disease

iMAb - Iama collaboration
July, 2019
iMAb and Iama announce the launch of a discovery program for novel immunotherapy antibodies

7th AIS - Tours, France

June 24-25, 2019

Meet iMAb at the 7th Antibody Industrial Symposium 2019 (AIS2019). This year's topic is “Harnessing the immune system with therapeutic antibodies”

iMAb - ADC Therapeutics collaboration
April 9, 2019
iMAb and ADC Therapeutics team up to discover novel therapeutic human antibodies

FESTIVAL OF BIOLOGICS 2019 - San Diego, USA

March 4-5, 2019

Meet iMAb at the Festival of Biologics, at the Americas Antibody Congress bringing together the pioneers doing the most innovative work within the industry and across the whole value chain.

BIO-EUROPE 2018 - Copenhagen, Danmark

November 5-7, 2018

Meet iMAb at the 24th annual BIO-Europe, Europe's largest partnering conference serving the global biotechnology industry

FESTIVAL OF BIOLOGICS 2018 - basel switzerland

October 29-31, 2018

Meet iMAb at the Festival of Biologics, a technology exhibition for the biologics community gathering 1200 antibody, biosimilar, immunotherapy and high potency API development professionals, as well as leading academics and innovative suppliers.